|
WO2020102596A1
|
|
Deuterated compounds, compositions, and uses
|
|
WO2019204582A1
|
|
Stabilized polyunsaturated compounds and uses thereof
|
|
EP3773541A1
|
|
Isotopically modified composition and therapeutic uses thereof
|
|
US2019282529A1
|
|
Isotopically modified components and therapeutic uses thereof
|
|
WO2017192460A1
|
|
Isotopically modified composition and therapeutic uses thereof
|
|
WO2017062992A1
|
|
Improving quality of mitochondrial dna measurements for use in assessing mitochondrial dysfunctions
|
|
CN108698987A
|
|
The locus specificity isotope labelling of 1,4- diene systems
|
|
CN106170206A
|
|
Optic neuropathy treatment and the oxidative stress with stable many unsaturated materialss minimizing steroid induction
|
|
EP2701697A2
|
|
Oxidative retinal diseases
|
|
AU2012249917A1
|
|
Neurodegenerative disorders and muscle diseases implicating PUFAs
|
|
WO2012148929A2
|
|
Disorders implicating pufa oxidation
|
|
EP3730135A1
|
|
Impaired energy processing disorders and mitochondrial deficiency
|
|
EP3339315A1
|
|
Isotopically modified compounds and their use as food supplements
|
